prostate cancer tissue array slides  (Biomax Inc)

Journal: The Journal of Biological Chemistry

Article Title: Peroxiredoxin IV plays a critical role in cancer cell growth and radioresistance through the activation of the Akt/GSK3 signaling pathways

doi: 10.1016/j.jbc.2022.102123

Figure Lengend Snippet: Examination of Prx4 protein levels in patient specimens of prostate cancer by tissue microarray or established prostate cancer cell lines by Western blotting. A , tissue microarray slides and representative images of anti-Prx4 staining of prostate normal and adenocarcinoma. Positive anti-Prx4 staining shows in dark brown and counter staining for nuclear shows light blue . The scale bars represent 5 mm (whole slide), 500 μm (individual tumor), and 100 μm (zoomed in). B and C , anti-Prx4 staining intensity were quantitatively scored by board-certified pathologist and data were compared between prostate normal (n = 50) and adenocarcinoma (n = 66) ( B ), as well as between prostate normal and cancer with different levels of Gleason grading ( C ). D , examination of Prx4 levels in prostate derived nontumorigenic or tumor cell lines by Western blotting. The bar graph on the right shows quantitative data from three independent blots. ∗ p < 0.05 by two-way ANOVA. Prx, peroxiredoxin.

Article Snippet: Human prostate normal and prostate cancer tissue microarray slides were commercially obtained, including BNS19011 and PR803d (US Biomax).

Techniques: Microarray, Western Blot, Staining, Derivative Assay

Journal: International Journal of Cancer

Article Title: Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer

doi: 10.1002/ijc.32535

Figure Lengend Snippet: Reduced OLFM4 expression is associated with higher Gleason scores and lower recurrence‐free survival in human primary prostate adenocarcinoma. ( a ) Representative images of HE staining and immunohistochemistry (IHC) analysis of OLFM4 protein expression in adjacent normal and tumor regions of whole‐mount section human prostate cancer tissue specimens (obtained from the Laboratory of Pathology, National Cancer Institute). All micrographs shown are for tissues obtained from the same case. LT, lower grade tumor (Gleason grade 3, GL. 3); HT, higher grade tumor Gleason grade 4, GL. 4). Scale bars: 50 μm. ( b ) Quantitation of OLFM4 protein expression from immunohistochemical analyses using human prostate cancer tissue slides obtained from CHTN and US Biomax. Data represent the mean ± standard deviation (SD) of 3,3′‐diaminobenzidine (DAB) intensity normalized to the number of nuclei. Adjacent Nor., normal tissue adjacent to primary tumor; Gleason score ≤4 + 3; Gleason score ≥4 + 4. We excluded CHTN and US Biomax cases with quality issues for which we could not obtain immunohistochemistry data. *** p ≤ 0.001 (ANOVA). ( c ) OLFM4 mRNA expression in prostate cancer specimens in data downloaded from the GSE21032 dataset. Data represent the mean ± SD. Normal, normal tissue adjacent to primary tumor; P‐tumor, primary tumor; M‐PCs; prostate tumor with distant metastasis. ** p ≤ 0.01; *** p ≤ 0.001 (ANOVA). ( d ) Kaplan–Meier plot of recurrence‐free survival for OLFM4 mRNA higher‐expressing (red line) and lower‐expressing (blue line) prostate adenocarcinoma patient cohorts in the GSE21032 dataset at 25% thresholds ( p = 0.0000154; log‐rank test).

Article Snippet: Human prostate cancer tissue array slides (for 70 prostate cancer cases and 10 normal tissues) were purchased from US Biomax (PR803, Rockville, MD).

Techniques: Expressing, Staining, Immunohistochemistry, Quantitation Assay, Immunohistochemical staining, Standard Deviation